In the present pilot study, we intend to test phenotypic flexibility (Phenflex) in 20 clinically stable patients with COPD by exploring their response to a dietary challenge test before and after pulmonary rehabilitation. Moreover, the baseline…
ID
Source
Brief title
Condition
- Appetite and general nutritional disorders
- Respiratory disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameter is to explore if there is an association between the
pulmonary rehabilitation and the *metabolic age* or metabolic resilience,
measured with the composite biomarker. The composite biomarker is based on
blood response curves (t=0, 30, 60, 120 and 240 minutes) of six blood
parameters after consumption of the PhenFlex drink: glucose, C-peptide,
non-esterified fatty acids, cholesterol, HDL-cholesterol, triglycerides. The
parameters are measured in blood. The composite biomarker will be reported as a
health score, which is calculated by combining the outcome of the separate
measures.
Secondary outcome
To explore associations between the metabolic resilience and the change in the
above described biomarkers after pulmonary rehabilitation. Moreover, the change
in the regular outcomes of pulmonary rehabilitation will be studied: health
status (using the COPD Assessment Test (CAT)), mood status (using the Hospital
Anxiety and Depression Scale (HADS)), exercise performance (using the
cardiopulmonary exercise tests (CPET) (only at baseline), 6-min walk distance
(6 MWT) and constant work rate cycling test (CWRT)), muscle strength and
endurance (using the BIODEX computerized dynamometer), degree of symptoms
(using the modified Medical Research Council (mMRC) dyspnea grade and the
Checklist Individual Strength (CIS) fatigue domain), resting blood pressure
measures (systolic and diastolic blood pressure), and body composition (with
focus on body weight, waist circumference, fat-free mass and fat mass using DXA
scanning). To explore associations between the change in phenotypic flexibility
of COPD patients before and after rehabilitation and variables associated with
phenotypic flexibility will also be studied: lifestyle measured with the
lifestyle and health questionnaire, food intake measured by the Eetscore
questionnaire, and optional stress with hair cortisol levels. The validity of
continuous vital sign monitoring by a non-invasive health patch in COPD
patients shall be evaluated.
Background summary
Chronic obstructive pulmonary disease (COPD) is primary a chronic respiratory
disease characterized by persistent airflow limitation. However, COPD is today
recognized as a systemic disease with multiple co-morbidities and
extra-pulmonary features. Indeed, patients with COPD suffer more from
alterations in body composition, osteoporosis and hyperglycaemia compared to an
age-matched control group (Triest et al. unpublished data). Furthermore, about
30% of the patients with COPD have continuous low-grade systemic inflammation.
Due to the parallelism between the progression of COPD and the ageing process,
it has been proposed that COPD can be a syndrome of accelerated ageing. Based
on telomere length, a COPD patient has a biological age of on average 8 years
older compared to a control subject with the same age. From this point of view,
it is reasonable to hypothesis that the metabolic flexibility of a patient with
COPD is different compared to an age-matched healthy peer.
In nutrition and health research, there is a growing awareness that health is
determined by the ability to maintain or regain homeostasis after various
physiologic stresses and that this characteristic can be used to study and
quantify the effects of nutrients or nutrition on multiple aspects of health.
In a recent study, the WHO definition of health originating from 1948 is
reconsidered and redefined as *the resilience of homeostatic control*: the
ability to cope with daily challenges without drifting out the regulated
homeostatic/allostatic zone. In short, this concept describes health as *an
ability to adapt* to various day-to-day challenges (e.g. strenuous exercise or
dietary challenge). Pulmonary rehabilitation may change the resilience of
homeostatic control.
Study objective
In the present pilot study, we intend to test phenotypic flexibility (Phenflex)
in 20 clinically stable patients with COPD by exploring their response to a
dietary challenge test before and after pulmonary rehabilitation. Moreover, the
baseline results of the present pilot study will be compared with the results
of the control subjects obtained in study CHDR1230, in which 100 female and
male subjects within the ranges of a healthy population were measured and with
20 male type 2 diabetic subjects that participated in study CHDR1211. This
pilot study aims also to explore phenotypic flexibility of COPD patients before
and after pulmonary rehabilitation, as pulmonary rehabilitation is expected to
have a positive effect of patients* health.
Study design
The study is a single center, explorative observational pilot study with a
dietary challenge test before and after rehabilitation
Intervention
During the test day before and after pulmonary rehabilitation a high calorie
dietary challenge drink, the so called Phenflex drink will be administered to
all volunteers. This 500 mL drink contains 75 g glucose, 20 g Protifar
(Nutricia), 60 g palm oil, flavour and 345 mL water.
Study burden and risks
The total engery intake of 900 kcal at once cold cause a feeling of nausea or
abdominal bloating. To reduce the already minimal potential risk, subject with
a reported food allergy or sensitivity for one of the used ingredients will be
excluded from study participation. Due to the long fasting period, the patient
can feel dizzy or have headach. Inserting a cannula can be painful and a bruise
can be a consequence of the cannula.
The health patch may cause irritation of the skin in some individuals. If
participants experience irritation caused by the health patch, the health patch
will be removed but the participants can continue with the study.
Hornerheide 1
Horn 6085 NM
NL
Hornerheide 1
Horn 6085 NM
NL
Listed location countries
Age
Inclusion criteria
- Objective diagnosis of COPD
- Approval for a pulmonary rehabilitation program (inpatient or outpatient) of
Ciro after start assessment
Exclusion criteria
- Clinically important pulmonary disease other than COPD
- Participation in an investigational drug within 3 months prior to screening.
- Unacceptable concomitant medication use at baseline, e.g., drugs known or
likely to interact with the challenge drink or study assessments.
- Reported food allergy or sensitivity for one of the used ingredients of the
Phenflex shake
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
Register | ID |
---|---|
CCMO | NL62032.028.19 |
Other | Trial NL7793 |